These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

714 related articles for article (PubMed ID: 29174699)

  • 1. Neoteric advancement in TB drugs and an overview on the anti-tubercular role of peptides through computational approaches.
    Khusro A; Aarti C; Barbabosa-Pliego A; Salem AZM
    Microb Pathog; 2018 Jan; 114():80-89. PubMed ID: 29174699
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Delamanid, Bedaquiline, and Linezolid Minimum Inhibitory Concentration Distributions and Resistance-related Gene Mutations in Multidrug-resistant and Extensively Drug-resistant Tuberculosis in Korea.
    Yang JS; Kim KJ; Choi H; Lee SH
    Ann Lab Med; 2018 Nov; 38(6):563-568. PubMed ID: 30027700
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Anti-tubercular peptides: A quest of future therapeutic weapon to combat tuberculosis.
    Khusro A; Aarti C; Agastian P
    Asian Pac J Trop Med; 2016 Nov; 9(11):1023-1034. PubMed ID: 27890360
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In vitro interaction profiles of the new antitubercular drugs bedaquiline and delamanid with moxifloxacin against clinical Mycobacterium tuberculosis isolates.
    Chandramohan Y; Padmanaban V; Bethunaickan R; Tripathy S; Swaminathan S; Ranganathan UD
    J Glob Antimicrob Resist; 2019 Dec; 19():348-353. PubMed ID: 31226332
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Development of antituberculous drugs: current status and future prospects].
    Tomioka H; Namba K
    Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bedaquiline and delamanid for drug-resistant tuberculosis: a clinician's perspective.
    Guglielmetti L; Chiesi S; Eimer J; Dominguez J; Masini T; Varaine F; Veziris N; Ader F; Robert J
    Future Microbiol; 2020 Jun; 15():779-799. PubMed ID: 32700565
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In vitro activity of collinin isolated from the leaves of Zanthoxylum schinifolium against multidrug- and extensively drug-resistant Mycobacterium tuberculosis.
    Kim S; Seo H; Mahmud HA; Islam MI; Lee BE; Cho ML; Song HY
    Phytomedicine; 2018 Jul; 46():104-110. PubMed ID: 30097109
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Determination of MIC distribution and epidemiological cutoff values for bedaquiline and delamanid in Mycobacterium tuberculosis using the MGIT 960 system equipped with TB eXiST.
    Keller PM; Hömke R; Ritter C; Valsesia G; Bloemberg GV; Böttger EC
    Antimicrob Agents Chemother; 2015 Jul; 59(7):4352-5. PubMed ID: 25941226
    [TBL] [Abstract][Full Text] [Related]  

  • 9. New treatment options for multidrug-resistant tuberculosis.
    Field SK; Fisher D; Jarand JM; Cowie RL
    Ther Adv Respir Dis; 2012 Oct; 6(5):255-68. PubMed ID: 22763676
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Anti-tuberculosis lead molecules from natural products targeting Mycobacterium tuberculosis ClpC1.
    Lee H; Suh JW
    J Ind Microbiol Biotechnol; 2016 Mar; 43(2-3):205-12. PubMed ID: 26586403
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Worldwide emergence of extensively drug-resistant tuberculosis.
    Shah NS; Wright A; Bai GH; Barrera L; Boulahbal F; Martín-Casabona N; Drobniewski F; Gilpin C; Havelková M; Lepe R; Lumb R; Metchock B; Portaels F; Rodrigues MF; Rüsch-Gerdes S; Van Deun A; Vincent V; Laserson K; Wells C; Cegielski JP
    Emerg Infect Dis; 2007 Mar; 13(3):380-7. PubMed ID: 17552090
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tuberculosis: clinical trials and new drug regimens.
    Kwon YS; Jeong BH; Koh WJ
    Curr Opin Pulm Med; 2014 May; 20(3):280-6. PubMed ID: 24614239
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A review of recent advances in anti-tubercular drug development.
    Umumararungu T; Mukazayire MJ; Mpenda M; Mukanyangezi MF; Nkuranga JB; Mukiza J; Olawode EO
    Indian J Tuberc; 2020 Oct; 67(4):539-559. PubMed ID: 33077057
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Plan to combat extensively drug-resistant tuberculosis: recommendations of the Federal Tuberculosis Task Force.
    Centers for Disease Control and Prevention (CDC)
    MMWR Recomm Rep; 2009 Feb; 58(RR-3):1-43. PubMed ID: 19214162
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Isoniazid derivatives and their anti-tubercular activity.
    Hu YQ; Zhang S; Zhao F; Gao C; Feng LS; Lv ZS; Xu Z; Wu X
    Eur J Med Chem; 2017 Jun; 133():255-267. PubMed ID: 28390957
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Recent controversies about MDR and XDR-TB: Global implementation of the WHO shorter MDR-TB regimen and bedaquiline for all with MDR-TB?
    Dheda K; Cox H; Esmail A; Wasserman S; Chang KC; Lange C
    Respirology; 2018 Jan; 23(1):36-45. PubMed ID: 28850767
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Coumarin hybrid derivatives as promising leads to treat tuberculosis: Recent developments and critical aspects of structural design to exhibit anti-tubercular activity.
    Reddy DS; Kongot M; Kumar A
    Tuberculosis (Edinb); 2021 Mar; 127():102050. PubMed ID: 33540334
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bedaquiline and delamanid in tuberculosis.
    Esposito S; Bianchini S; Blasi F
    Expert Opin Pharmacother; 2015; 16(15):2319-30. PubMed ID: 26293803
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Synthesis and bioactivity of antitubercular peptides and peptidomimetics: an update.
    De Leon Rodriguez LM; Kaur H; Brimble MA
    Org Biomol Chem; 2016 Jan; 14(4):1177-87. PubMed ID: 26645944
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Recent developments of coumarin-containing derivatives and their anti-tubercular activity.
    Hu YQ; Xu Z; Zhang S; Wu X; Ding JW; Lv ZS; Feng LS
    Eur J Med Chem; 2017 Aug; 136():122-130. PubMed ID: 28494250
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 36.